Chih-Yi Liao

Dr. Chih-Yi Liao

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2022 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
OAOsman Ahmed
Osman Ahmed
QYQian Yu
Qian Yu
MPMikin Patel
Mikin Patel
GHGloria Hwang
Gloria Hwang
APAnjana Pillai
Anjana Pillai
TBTalia Baker
Talia Baker

29 August 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
RGRushabh Gujarathi
Rushabh Gujarathi
JFJoseph W. Franses
Joseph W. Franses
APAnjana Pillai
Anjana Pillai
CLChih-Yi Liao
Chih-Yi Liao
Targeted therapies are the mainstay of systemic therapies for patients with advanced, unresectable, or metastatic hepatocellular carcinoma. Several therapeutic targets, such as c-Met, TGF-β, and FGFR, have been evaluated in the past, though results from these clinical studies failed to show clinical benefit. However, these remain important targets for the future with novel targeted agents and strategies. The Wnt/β-catenin signaling pathway, c-Myc oncogene, GPC3, PPT1 are exciting novel targets, among others, currently undergoing evaluation. Through this review, we aim to provide an overview of previously evaluated and potentially novel therapeutic targets and explore their continued relevance in ongoing and future studies for HCC.

1 August 2023 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
QYQian Yu
Qian Yu
MPMikin Patel
Mikin Patel
DKDaniel Kwak
Daniel Kwak
EUEthan Ungchusri
Ethan Ungchusri
YWYating Wang
Yating Wang
OAOsman Ahmed
Osman Ahmed

2 August 2024 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
RGRushabh Gujarathi
Rushabh Gujarathi
SASara Abou Azar
Sara Abou Azar
JTJoseph Tobias
Joseph Tobias
BPBlase N. Polite
Blase N. Polite
NSNamrata Setia
Namrata Setia
CLChih-Yi Liao
Chih-Yi Liao
Pre-clinical data suggest that mutations in the MEN1, DAXX, and/or ATRX genes may potentially increase radiation efficacy in cancer cells. Herein, we explore the association between response to peptide receptor radionuclide therapy (PRRT) and those mutations in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). We analyzed tissue-based next generation sequencing (NGS) assay results and clinicopathologic data from 28 patients with GEP-NETs treated with PRRT. Findings were correlated with progression-free survival (PFS) and objective response rate (ORR). Patients with mutations in MEN1, DAXX, and/or ATRX (n = 13) had a longer median PFS (26.47 vs 12.13 months; P = 0.014) than wild-type (n = 15) patients when adjusted for surgery prior to PRRT, tumor grade, and presence of TP53 mutation. Alterations in MEN1 along with a concurrent mutation in either DAXX or ATRX (n = 6) trended toward longer PFS compared to patients without concurrent mutations (31.53 vs 17.97 months; P = 0.09). ORR was higher in patients with a mutation in MEN1, DAXX, or ATRX (41.67% vs 15.38%). In pancreatic NET patients, these target mutations also showed a longer PFS (28.43 vs 9.83 months; P = 0.04). TP53 alterations showed a shorter PFS than wild-type cases (11.17 vs 20.47 months; P = 0.009). Mutations in MEN1/DAXX/ATRX are associated with improved PFS in patients with GEP-NETs receiving PRRT and might be used as a biomarker for treatment response.

30 September 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
JHJames J Harding
James J Harding
DODo-Youn Oh
Do-Youn Oh
TMTeresa Macarulla Mercade
Teresa Macarulla Mercade
LGLipika Goyal
Lipika Goyal
AVAndreas Varkaris
Andreas Varkaris
JRJordi Rodon
Jordi Rodon
Purpose: Isocitrate dehydrogenase (IDH) 1/2–isoform inhibitors have clinical efficacy in IDH1/IDH2-mutated neoplasms. However, primary resistance and secondary resistance limit their therapeutic potential. LY3410738, an oral, brain-penetrant, dual IDH1/IDH2-mutated isoform-selective inhibitor, was designed to overcome resistance. Patients and Methods: This global, multicenter, open-label, phase I study of patients with IDH-mutant solid tumors evaluated LY3410738 as monotherapy (dose escalation) for advanced solid tumors in combination with cisplatin–gemcitabine (CISGEM) for newly diagnosed cholangiocarcinoma or with durvalumab for relapsed/refractory cholangiocarcinoma (dose expansion; NCT04521686). Primary objectives were the maximum tolerated dose, recommended phase II dose, and preliminary antitumor activity. Safety, pharmacokinetics, inhibition of D-2-hydroxyglutarate, and ctDNA were assessed. Results: Overall, 119 patients received LY3410738 alone (N = 94) or in combination with CISGEM (N = 19) or durvalumab (N = 6). No dose-limiting toxicities were observed; the maximum tolerated dose was not determined. Common adverse events included nausea, vomiting, and decreased appetite. Overall response rates of 5.2% and 11.1% and disease control rates of 56.9% and 63.0% were observed for patients with relapsed/refractory IDH1- or IDH2-mutant cholangiocarcinoma or IDH1-mutant glioma, respectively. D-2-hydroxyglutarate normalization was rapid and durable. In dose-expansion cohorts, combination treatments were tolerable, with one dose-limiting toxicity in the durvalumab cohort. LY3410738 plus CISGEM demonstrated a response rate of 42.1%, a median duration of response of 8.1 months, and a median progression-free survival of 10.2 months for patients with newly diagnosed IDH-mutant cholangiocarcinoma. Conclusions: LY3410738 demonstrated largely cytostatic antitumor activity in IDH1- or IDH2-mutated cholangiocarcinoma and IDH1-mutated gliomas. LY3410738 plus CISGEM exhibited favorable antitumor activity in patients with treatment-naïve IDH-mutated cholangiocarcinoma, warranting further exploration as a treatment strategy.

11 October 2024 in Surgery
Verified
Journal Article
Closed access
JTJoseph Tobias
Joseph Tobias
SASara Abou Azar
Sara Abou Azar
RGRushabh Gujarathi
Rushabh Gujarathi
RNRachel Nordgren
Rachel Nordgren
TVTanaz Vaghaiwalla
Tanaz Vaghaiwalla
XKXavier M. Keutgen
Xavier M. Keutgen